Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin Pays $70M Upfront for Second Fabry Disease Therapy

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$56.4
Mkt Cap
$10.84B
52W Low
$49.259
52W High
$70.98
52W Position info
14% above low
Off High info
21% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BMRN is trading near its 52-week low of $49.259 (14% above the low).

Summary

BioMarin is licensing HM15421/GC1134A, an investigational next-generation enzyme replacement therapy for Fabry disease, from GC Biopharma and Hanmi Pharm on an exclusive worldwide basis outside Korea. It pays $70 million upfront, with the partners eligible for up to $405 million in milestones and royalties; GC and Hanmi keep commercialization rights in Korea while BioMarin takes sole responsibility elsewhere. The deal adds a second potential Fabry treatment to a portfolio that already includes its marketed enzyme replacement therapy, extending the rare-disease franchise rather than opening a new one. The upfront is modest against a company of this size, but the milestone structure ties most of the payout to clinical and commercial success. This follows the August Alesta Therapeutics acquisition and the October 6th disclosure of a $283 million Q3 IPR&D charge tied to that deal — BioMarin is clearly still shopping for pipeline assets. Q3 results will show whether the string of deal-related charges is pressuring EPS.

At the time of this announcement, BMRN was trading at $56.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BMRN - Latest Insights

BMRN
Nov 03, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $55.66
Real-time Price: $60.65 info
Change: +$4.99 (+9%) info
Market Cap: $11.74B info
BMRN
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.79
Real-time Price: $60.65 info
Change: +$5.85 (+11%) info
Market Cap: $11.74B info
BMRN
Nov 02, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $57.44
Real-time Price: $60.65 info
Change: +$3.21 (+6%) info
Market Cap: $11.74B info
BMRN
Oct 06, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $56.22
Real-time Price: $60.65 info
Change: +$4.43 (+8%) info
Market Cap: $11.74B info
BMRN
Aug 31, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.95
Real-time Price: $60.65 info
Change: -$7.31 (-11%) info
Market Cap: $11.74B info